Phase I Study of High-Dose L-methylfolate in Combination with Temozolomide and Bevacizumab in Recurrent IDH wild-type High-Grade Glioma.
- 2022-01-05
- Clinical Trial
- Cancer research communications 2(1)
- Lucas A Salas
- Thomas G Stewart
- Bret C Mobley
- Chengwei Peng
- Jing Liu
- Sudan N Loganathan
- Jialiang Wang
- Yanjun Ma
- Mitchell S Berger
- Devin Absher
- Yang Hu
- Paul L Moots
- Brock C Christensen
- Stephen W Clark
- PubMed: 35392283
- DOI: 10.1158/2767-9764.crc-21-0088
- Moderate evidence
- Clinical
LMF treated had mOS of 9.5 months (95% CI, 9.1-35.4) comparable to bevacizumab historical control 8.6 months (95% CI, 6.8-10.8).
- Effect
- Neutral
- Effect size
- Small
- Significant
- No
- Dose
- 15, 30, 60, or 90 mg daily